optimizing first-line immunotherapy for recurrent or metastatic hnscc
Published 2 months ago • 8 plays • Length 6:00Download video MP4
Download video MP3
Similar videos
-
6:00
optimizing first-line immunotherapy for recurrent or metastatic hnscc
-
33:50
immunotherapy for recurrent or metastatic hnscc: what are the practical considerations?
-
6:30
the role of immunotherapy in the treatment of recurrent or metastatic hnscc: the evidence
-
6:30
the role of immunotherapy in the treatment of recurrent or metastatic hnscc: the evidence
-
6:46
first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma
-
5:14
immunotherapy for recurrent hnscc
-
7:03
lba8_pr - keynote-048: phase 3 study of first-line pembrolizumab in r/m hnscc
-
5:24
keynote048: first line pembrolizumab for r/m hnscc
-
38:21
navigating the challenges of treatment provision in recurrent/metastatic hnscc
-
33:15
optimizing the management of squamous cell carcinoma of the head and neck with immunotherapeutic ...
-
5:34
pembrolizumab for recurrent hnscc
-
1:13
keynote-b84: pepinemab pembrolizumab for metastatic/recurrent head & neck squamous cell carcinoma
-
4:42
pembrolizumab for recurrent head and neck squamous cell carcinomas (hnscc)
-
0:55
dr. cohen on immunotherapy in head and neck squamous cell carcinoma
-
3:55
checkpoint inhibitors for recurrent hnscc
-
4:38
emerging checkpoint inhibitors for hnscc
-
4:41
immunotherapy combinations for hnscc
-
11:57
immunotherapy in hnscc
-
1:37
mono or combination immunotherapy for hnscc?